Immuron Submits IND Application To FDA for Travelan
05. Dezember 2022 06:00 ET
|
Immuron Limited
Highlights: Investigational New Drug (IND) application submitted to the U.S. Food and Drug administration (FDA)Plans in place to initiate a Human clinical trial in 60 healthy volunteers in the...
Immuron completes strategic investment in leading gut health biotech Ateria Health
16. November 2022 07:00 ET
|
Immuron Limited
Highlights: Immuron has completed settlement of strategic investment in leading gut health biotech Ateria Health, in accordance with signed subscription and option agreement (announced 13 October...
Immuron CEO, Steven Lydeamore to present at AusBioInvest
26. Oktober 2022 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two...
Immuron strategic investment in leading gut health biotech Ateria Health
13. Oktober 2022 06:00 ET
|
Immuron Limited
Highlights: Immuron has signed a subscription and option agreement with leading gut health biotech Ateria Health: Strategic investment of approximately £1.5m (A$2.6m) to acquire an initial 17.5% of...
Immuron Executes Travelan Clinical Trial Agreement with US-based Pharmaron
04. Oktober 2022 06:00 ET
|
Immuron Limited
Highlights: Clinical Trial Master Service Agreement with US-based Pharmaron ExecutedInvestigational New Drug (IND) application to be submitted to the U.S. Food and Drug administration (FDA)Plans in...
Immuron CEO, Steven Lydeamore, to host an investor webinar
29. August 2022 07:00 ET
|
Immuron Limited
MELBOURNE, Australia, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for...
Immuron Update on IMM-124E SARS-CoV-2 Research
19. August 2022 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for...
Immuron US DoD Naval Medical Research Center Receives feedback on IND Application for New Campylobacter ETEC Therapeutic
26. Juli 2022 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, July 26, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron North American Travelan® Sales up 494% and Global sales up 431%
11. Juli 2022 06:00 ET
|
Immuron Limited
Highlights: North American FY22 Travelan® sales increased by +494% to $0.6MGlobal sales increased by 431% to $0.9MAustralian FY22 sales increased by 318% to $0.3M MELBOURNE, Australia, July 11,...
Immuron Receives European Patent Notification on Drug Composition to Treat Clostridioides difficile Associated Disease
07. Juli 2022 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, July 07, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...